Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of novel therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
View Top Employees from OnyvaxWebsite | http://www.onyvax.com |
Revenue | $16.2 million |
Funding | $5.6 million |
Employees | 2 (2 on RocketReach) |
Founded | 1997 |
Phone | +44 20 8682 9494 |
Technologies |
JavaScript,
HTML,
Google Analytics
+9 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Therapeutics |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Onyvax employee's phone or email?
The Onyvax annual revenue was $16.2 million in 2024.
Ajay Angris is the Head of Laboratory and Facility Management of Onyvax.
2 people are employed at Onyvax.
The NAICS codes for Onyvax are [32, 325, 3254].
The SIC codes for Onyvax are [28, 283].